{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:13Z","timestamp":1792784893788,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Mount Sinai Hospital Department of Pathology and Laboratory Medicine"},{"name":"Washington University School of Medicine Department of Pathology and Immunology"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41379-022-01115-6","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T01:03:16Z","timestamp":1654909396000},"page":"1656-1666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Xanthogranulomatous epithelial tumors and keratin-positive giant cell-rich soft tissue tumors: two aspects of a single entity with frequent HMGA2-NCOR2 fusions"],"prefix":"10.1016","volume":"35","author":[{"given":"Carina A.","family":"Dehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2269-6216","authenticated-orcid":false,"given":"Brendan C.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4144-8824","authenticated-orcid":false,"given":"Elizabeth G.","family":"Demicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7138-0923","authenticated-orcid":false,"given":"John S.A.","family":"Chrisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-022-01115-6_bib1","doi-asserted-by":"crossref","unstructured":"Fritchie, K. J., Torres-Mora, J., Inwards, C., Thway, K., Vaiyapuri, S., Jackson, R. et al. Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women. Mod Pathol33, 1889-1895 (2020).","DOI":"10.1038\/s41379-020-0562-8"},{"key":"10.1038\/s41379-022-01115-6_bib2","doi-asserted-by":"crossref","unstructured":"Agaimy, A., Michal, M., Stoehr, R., Ferrazzi, F., Fabian, P., Michal, M. et al. Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors. Mod Pathol34, 1507-1520 (2021).","DOI":"10.1038\/s41379-021-00789-8"},{"key":"10.1038\/s41379-022-01115-6_bib3","doi-asserted-by":"crossref","unstructured":"Dickson, B. C. & Swanson, D. Targeted RNA sequencing: A routine ancillary technique in the diagnosis of bone and soft tissue neoplasms. Genes Chromosomes Cancer58, 75-87 (2019).","DOI":"10.1002\/gcc.22690"},{"key":"10.1038\/s41379-022-01115-6_bib4","doi-asserted-by":"crossref","unstructured":"Robinson, J. T., Thorvaldsd\u00f3ttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G. et al. Integrative genomics viewer. Nat Biotechnol29, 24-26 (2011).","DOI":"10.1038\/nbt.1754"},{"key":"10.1038\/s41379-022-01115-6_bib5","doi-asserted-by":"crossref","unstructured":"Thorvaldsd\u00f3ttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform14, 178-192 (2013).","DOI":"10.1093\/bib\/bbs017"},{"key":"10.1038\/s41379-022-01115-6_bib6","doi-asserted-by":"crossref","unstructured":"Robinson, J. T., Thorvaldsd\u00f3ttir, H., Wenger, A. M., Zehir, A. & Mesirov, J. P. Variant Review with the Integrative Genomics Viewer. Cancer Res77, e31-e34 (2017).","DOI":"10.1158\/0008-5472.CAN-17-0337"},{"key":"10.1038\/s41379-022-01115-6_bib7","doi-asserted-by":"crossref","unstructured":"Treffel, M., Lardenois, E., Larousserie, F., Karanian, M., Gomez-Brouchet, A., Bouvier, C. et al. Denosumab-treated Giant Cell Tumors of Bone: A Clinicopathologic Analysis of 35 Cases From the French Group of Bone Pathology. Am J Surg Pathol44, 1-10 (2020).","DOI":"10.1097\/PAS.0000000000001388"},{"key":"10.1038\/s41379-022-01115-6_bib8","doi-asserted-by":"crossref","unstructured":"Wojcik, J., Rosenberg, A. E., Bredella, M. A., Choy, E., Hornicek, F. J., Nielsen, G. P. et al. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone. Am J Surg Pathol40, 72-80 (2016).","DOI":"10.1097\/PAS.0000000000000506"},{"key":"10.1038\/s41379-022-01115-6_bib9","doi-asserted-by":"crossref","unstructured":"Oliveira, A. M., Dei Tos, A. P., Fletcher, C. D. & Nascimento, A. G. Primary giant cell tumor of soft tissues: a study of 22 cases. Am J Surg Pathol24, 248-256 (2000).","DOI":"10.1097\/00000478-200002000-00011"},{"key":"10.1038\/s41379-022-01115-6_bib10","doi-asserted-by":"crossref","unstructured":"Ho, J., Peters, T., Dickson, B. C., Swanson, D., Fernandez, A., Frova-Seguin, A. et al. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors. Genes Chromosomes Cancer59, 96-105 (2020).","DOI":"10.1002\/gcc.22807"},{"key":"10.1038\/s41379-022-01115-6_bib11","doi-asserted-by":"crossref","unstructured":"West, R. B., Rubin, B. P., Miller, M. A., Subramanian, S., Kaygusuz, G., Montgomery, K. et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A103, 690-695 (2006).","DOI":"10.1073\/pnas.0507321103"},{"key":"10.1038\/s41379-022-01115-6_bib12","doi-asserted-by":"crossref","unstructured":"Mehine, M., Kaasinen, E., M\u00e4kinen, N., Katainen, R., K\u00e4mpj\u00e4rvi, K., Pitk\u00e4nen, E. et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med369, 43-53 (2013).","DOI":"10.1056\/NEJMoa1302736"},{"key":"10.1038\/s41379-022-01115-6_bib13","unstructured":"Quade, B. J., Weremowicz, S., Neskey, D. M., Vanni, R., Ladd, C., Dal Cin, P. et al. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res63, 1351-1358 (2003)."},{"key":"10.1038\/s41379-022-01115-6_bib14","doi-asserted-by":"crossref","unstructured":"Tallini, G., Vanni, R., Manfioletti, G., Kazmierczak, B., Faa, G., Pauwels, P. et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest80, 359-369 (2000).","DOI":"10.1038\/labinvest.3780040"},{"key":"10.1038\/s41379-022-01115-6_bib15","doi-asserted-by":"crossref","unstructured":"Rabban, J. T., Dal Cin, P. & Oliva, E. HMGA2 rearrangement in a case of vulvar aggressive angiomyxoma. Int J Gynecol Pathol25, 403-407 (2006).","DOI":"10.1097\/01.pgp.0000209572.54457.7b"},{"key":"10.1038\/s41379-022-01115-6_bib16","doi-asserted-by":"crossref","unstructured":"Rawlinson, N. J., West, W. W., Nelson, M. & Bridge, J. A. Aggressive angiomyxoma with t(12;21) and HMGA2 rearrangement: report of a case and review of the literature. Cancer Genet Cytogenet181, 119-124 (2008).","DOI":"10.1016\/j.cancergencyto.2007.11.008"},{"key":"10.1038\/s41379-022-01115-6_bib17","doi-asserted-by":"crossref","unstructured":"Bartuma, H., Hallor, K. H., Panagopoulos, I., Collin, A., Rydholm, A., Gustafson, P. et al. Assessment of the clinical and molecular impact of different cytogenetic subgroups in a series of 272 lipomas with abnormal karyotype. Genes Chromosomes Cancer46, 594-606 (2007).","DOI":"10.1002\/gcc.20445"},{"key":"10.1038\/s41379-022-01115-6_bib18","doi-asserted-by":"crossref","unstructured":"Panagopoulos, I., Gorunova, L., Bjerkehagen, B., Lobmaier, I. & Heim, S. The recurrent chromosomal translocation t(12;18)(q14~15;q12~21) causes the fusion gene HMGA2-SETBP1 and HMGA2 expression in lipoma and osteochondrolipoma. Int J Oncol47, 884-890 (2015).","DOI":"10.3892\/ijo.2015.3099"},{"key":"10.1038\/s41379-022-01115-6_bib19","doi-asserted-by":"crossref","unstructured":"Panagopoulos, I., Gorunova, L., Agostini, A., Lobmaier, I., Bjerkehagen, B. & Heim, S. Fusion of the HMGA2 and C9orf92 genes in myolipoma with t(9;12)(p22;q14). Diagn Pathol11, 22 (2016).","DOI":"10.1186\/s13000-016-0472-8"},{"key":"10.1038\/s41379-022-01115-6_bib20","doi-asserted-by":"crossref","unstructured":"Dahl\u00e9n, A., Mertens, F., Rydholm, A., Brosj\u00f6, O., Wejde, J., Mandahl, N. et al. Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. Mod Pathol16, 1132-1140 (2003).","DOI":"10.1097\/01.MP.0000092954.42656.94"},{"key":"10.1038\/s41379-022-01115-6_bib21","doi-asserted-by":"crossref","unstructured":"Geurts, J. M., Schoenmakers, E. F., R\u00f6ijer, E., Astr\u00f6m, A. K., Stenman, G. & van de Ven, W. J. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene16, 865-872 (1998).","DOI":"10.1038\/sj.onc.1201609"},{"key":"10.1038\/s41379-022-01115-6_bib22","doi-asserted-by":"crossref","unstructured":"Panagopoulos, I., Gorunova, L., Andersen, H. K., Pedersen, T. D., L\u00f8mo, J., Lund-Iversen, M. et al. Genetic Characterization of Myoid Hamartoma of the Breast. Cancer Genomics Proteomics16, 563-568 (2019).","DOI":"10.21873\/cgp.20158"},{"key":"10.1038\/s41379-022-01115-6_bib23","doi-asserted-by":"crossref","unstructured":"Medeiros, F., Araujo, A. R., Erickson-Johnson, M. R., Kashyap, P. C., Dal Cin, P., Nucci, M. et al. HMGA1 and HMGA2 rearrangements in mass-forming endometriosis. Genes Chromosomes Cancer49, 630-634 (2010).","DOI":"10.1002\/gcc.20772"},{"key":"10.1038\/s41379-022-01115-6_bib24","doi-asserted-by":"crossref","unstructured":"Medeiros, F., Wang, X., Araujo, A. R., Erickson-Johnson, M. R., Lima, J. F., Meuter, A. et al. HMGA gene rearrangement is a recurrent somatic alteration in polypoid endometriosis. Hum Pathol43, 1243-1248 (2012).","DOI":"10.1016\/j.humpath.2011.09.013"},{"key":"10.1038\/s41379-022-01115-6_bib25","doi-asserted-by":"crossref","unstructured":"Muir, L. D., 2nd, Woelfle, J. D., Schowinsky, J. & Wilky, B. A. High grade sarcoma presenting as multifocal recurrent seromas after inguinal hernia repair: A case report. Rare Tumors12, 2036361320975746 (2020).","DOI":"10.1177\/2036361320975746"},{"key":"10.1038\/s41379-022-01115-6_bib26","doi-asserted-by":"crossref","unstructured":"Liu, J., Mao, R., Lao, I. W., Yu, L., Bai, Q., Zhou, X. et al. GLI1-altered mesenchymal tumor: a clinicopathological and molecular analysis of ten additional cases of an emerging entity. Virchows Arch (2021).","DOI":"10.1007\/s00428-021-03224-0"},{"key":"10.1038\/s41379-022-01115-6_bib27","doi-asserted-by":"crossref","unstructured":"Panagopoulos, I., Andersen, K., Gorunova, L., Lund-Iversen, M., Lobmaier, I. & Heim, S. Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (HMGA2) and Nuclear Receptor Co-repressor 2 (NCOR2) in Osteoclastic Giant Cell-rich Tumors of Bone. Cancer Genomics Proteomics19, 163-177 (2022).","DOI":"10.21873\/cgp.20312"},{"key":"10.1038\/s41379-022-01115-6_bib28","doi-asserted-by":"crossref","unstructured":"Brahmi, M., Alberti, L., Tirode, F., Karanian, M., Eberst, L., Pissaloux, D. et al. Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene. Ann Oncol29, 1488-1489 (2018).","DOI":"10.1093\/annonc\/mdy129"},{"key":"10.1038\/s41379-022-01115-6_bib29","doi-asserted-by":"crossref","unstructured":"Cupp, J. S., Miller, M. A., Montgomery, K. D., Nielsen, T. O., O'Connell, J. X., Huntsman, D. et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol31, 970-976 (2007).","DOI":"10.1097\/PAS.0b013e31802b86f8"},{"key":"10.1038\/s41379-022-01115-6_bib30","doi-asserted-by":"crossref","unstructured":"Martinez, A. P., Fritchie, K. J., Weiss, S. W., Agaimy, A., Haller, F., Huang, H. Y. et al. Histiocyte-rich rhabdomyoblastic tumor: rhabdomyosarcoma, rhabdomyoma, or rhabdomyoblastic tumor of uncertain malignant potential? A histologically distinctive rhabdomyoblastic tumor in search of a place in the classification of skeletal muscle neoplasms. Mod Pathol32, 446-457 (2019).","DOI":"10.1038\/s41379-018-0145-0"},{"key":"10.1038\/s41379-022-01115-6_bib31","doi-asserted-by":"crossref","unstructured":"Michal, M., Rubin, B. P., Kazakov, D. V., Michalov\u00e1, K., \u0160teiner, P., Grossmann, P. et al. Inflammatory leiomyosarcoma shows frequent co-expression of smooth and skeletal muscle markers supporting a primitive myogenic phenotype: a report of 9 cases with a proposal for reclassification as low-grade inflammatory myogenic tumor. Virchows Arch477, 219-230 (2020).","DOI":"10.1007\/s00428-020-02774-z"},{"key":"10.1038\/s41379-022-01115-6_bib32","doi-asserted-by":"crossref","unstructured":"Cloutier, J. M., Charville, G. W., Mertens, F., Sukov, W., Fritchie, K., Perry, K. D. et al. \u201cInflammatory Leiomyosarcoma\u201d and \u201cHistiocyte-rich Rhabdomyoblastic Tumor\u201d: a clinicopathological, immunohistochemical and genetic study of 13 cases, with a proposal for reclassification as \u201cInflammatory Rhabdomyoblastic Tumor\u201d. Mod Pathol34, 758-769 (2021).","DOI":"10.1038\/s41379-020-00703-8"},{"key":"10.1038\/s41379-022-01115-6_bib33","doi-asserted-by":"crossref","unstructured":"O'Connell, J. X., Wehrli, B. M., Nielsen, G. P. & Rosenberg, A. E. Giant cell tumors of soft tissue: a clinicopathologic study of 18 benign and malignant tumors. Am J Surg Pathol24, 386-395 (2000).","DOI":"10.1097\/00000478-200003000-00007"},{"key":"10.1038\/s41379-022-01115-6_bib34","doi-asserted-by":"crossref","unstructured":"Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P. et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet45, 1479-1482 (2013).","DOI":"10.1038\/ng.2814"},{"key":"10.1038\/s41379-022-01115-6_bib35","doi-asserted-by":"crossref","unstructured":"Amary, F., Berisha, F., Ye, H., Gupta, M., Gutteridge, A., Baumhoer, D. et al. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone. Am J Surg Pathol41, 1059-1068 (2017).","DOI":"10.1097\/PAS.0000000000000859"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01115-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01115-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01115-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:29:19Z","timestamp":1760228959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222002320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0893395222002320"],"URL":"https:\/\/doi.org\/10.1038\/s41379-022-01115-6","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Xanthogranulomatous epithelial tumors and keratin-positive giant cell-rich soft tissue tumors: two aspects of a single entity with frequent HMGA2-NCOR2 fusions","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-022-01115-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}